Company: NCEL
Filing Date: 2025-03-31
Form Type: F-4/A
Source: 0001213900-25-026428
Chunk: 264

Company: NewcelX Ltd.
Filing Date: 2025-03-31
Form: F-4/A
Chunk 264
---
 by reference into this proxy statement/prospectus. 132 KADIMASTEM BUSINESS Kadimastem is a clinical -stagepharmaceutical company focused on developing and manufacturing “off -the-shelf”, allogeneic, proprietary cell products based on its technology platform for the expansion and differentiation of hESCs into functional cells. Kadimastem’s vision is to: •Replace, restore and repair the functionality of diseased and malfunctioning cells in various degenerative diseases by transplantation of healthy and functional cells; and •Commercialize its proprietary cell lines optimized for both the cure of diabetes and the treatment of ALS, and other neurodegenerative diseases. Kadimastem is primarily developing two products: 1.AstroRx ®, Kadimastem’s lead product, which is an off -the-shelfcryopreserved cell therapy product in clinical development for the treatment for ALS and in pre -clinicalstudies for other neurodegenerative indications. AstroRx ®is comprised of fully differentiated astrocytes, which are mainly cells that support the CNS. 2.IsletRx is Kadimastem’s treatment for diabetes. IsletRx is comprised of functional, insulin and glucagon producing and releasing pancreatic islet cells, intended to treat and potentially cure patients with Type 1 diabetes and possibly Type 2 insulin dependent diabetes. Kadimastem was founded by Professor Michel Revel, Chief Scientific Officer of Kadimastem and Professor Emeritus of Molecular Genetics at the Weizmann Institute of Science. Professor Revel received the Israel Prize for the invention and development of Rebif ®, a multiple sclerosis blockbuster drug sold worldwide. Kadimastem is currently listed on the TASE (TASE: KDST). Kadimastem Overview Kadimastem is a clinical stage biotechnology company, with a unique platform for cell therapy that enables the production of off -the-shelfcell -basedproducts for the treatment of unmet medical needs. Kadimastem operates in the field of development of cell therapy, regenerative medicine, for the treatment of, among others, ALS, an incurable disease, for which Kadimastem received an orphan drug designation status from the FDA, as well as cell therapy in the field of regenerative medicine for the treatment of diabetes, a disease that affects hundreds of millions of people worldwide, and its product has the potential to provide a cure for the disease. Kadimastem intends to be a leading company in the field of regenerative medicine products for the treatment of